Trade ALT anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Altimmune, Inc. (ALT) is trading at US$3.11, down 4.17% today as of Aug 28, 15:29 EDT. The company has a market capitalisation of US$604.95M. Over the past 52 weeks, ALT has traded between US$2.56 and US$6.44. On Syfe you can trade ALT with $0 commission and add it to your watchlist.
| Previous close | US$3.24 |
|---|---|
| Market cap | US$604.95M |
| 52-week range | US$2.56 – US$6.44 |
| Volume | 2.24M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Altimmune, Inc.
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. Its lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Year: 2005
Altimmune's Investigational Alcohol Use Disorder Drug Meets Primary Endpoint in Phase 2 Study
Jul 28, 12:32 PM · MT Newswires
Altimmune Plans to Move Headquarters to New Jersey
Jun 17, 12:03 PM · MT Newswires
Altimmune Says Pemvidutide Data Show Metabolic Improvements in MASH Patients
May 28, 3:54 PM · MT Newswires
Altimmune's Phase 2b Trial Data for Pemvidutide Demonstrates Improvements in Liver Disease
May 27, 2:34 PM · MT Newswires
Altimmune, Inc. (ALT) stock is trading at US$3.11, -4.17% from the previous close of US$3.24.
The market cap for Altimmune, Inc. (ALT) stock is approximately US$604.95M.
The 52-week high for Altimmune, Inc. (ALT) stock is US$6.44.
The 52-week low for Altimmune, Inc. (ALT) stock is US$2.56.
Altimmune, Inc. (ALT) does not currently pay a dividend.
Stay on top of ALT
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
